Published in Oncotarget on September 30, 2016
Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2. Genes Dev (2003) 5.91
Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell (2002) 5.44
Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial-mesenchymal transition. J Cell Biol (2005) 5.00
An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. Science (2008) 4.89
Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci U S A (1996) 4.39
Role for Akt3/protein kinase Bgamma in attainment of normal brain size. Mol Cell Biol (2005) 4.00
Protein kinase B alpha/Akt1 regulates placental development and fetal growth. J Biol Chem (2003) 3.27
Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice. Cancer Res (2007) 3.13
Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1. Science (2013) 2.90
Isoform-specific regulation of insulin-dependent glucose uptake by Akt/protein kinase B. J Biol Chem (2003) 2.76
Regulation and function of the interleukin 13 receptor alpha 2 during a T helper cell type 2-dominant immune response. J Exp Med (2003) 2.71
A novel AKT3 mutation in melanoma tumours and cell lines. Br J Cancer (2008) 2.63
Cloning and characterization of a binding subunit of the interleukin 13 receptor that is also a component of the interleukin 4 receptor. Proc Natl Acad Sci U S A (1996) 2.57
Receptors for interleukin-13 and interleukin-4 are complex and share a novel component that functions in signal transduction. EMBO J (1993) 2.18
Akt2 overexpression plays a critical role in the establishment of colorectal cancer metastasis. Proc Natl Acad Sci U S A (2008) 2.04
Insulin increases the association of Akt-2 with Glut4-containing vesicles. J Biol Chem (1998) 1.95
Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma. Blood (2012) 1.92
Akt/protein kinase B isoforms are differentially regulated by epidermal growth factor stimulation. J Biol Chem (2000) 1.68
Gastrointestinal complications of pelvic radiotherapy: are they of any importance? Gut (2005) 1.37
Gastrointestinal symptoms after pelvic radiotherapy: a new understanding to improve management of symptomatic patients. Lancet Oncol (2007) 1.37
Gastrointestinal problems after pelvic radiotherapy: the past, the present and the future. Clin Oncol (R Coll Radiol) (2007) 1.33
Activation of Toll-like receptor 5 on breast cancer cells by flagellin suppresses cell proliferation and tumor growth. Cancer Res (2011) 1.30
Identification, purification, and characterization of a soluble interleukin (IL)-13-binding protein. Evidence that it is distinct from the cloned Il-13 receptor and Il-4 receptor alpha-chains. J Biol Chem (1997) 1.28
A specific role for AKT3 in the genesis of ovarian cancer through modulation of G(2)-M phase transition. Cancer Res (2006) 1.26
Radiation therapy and Toll-like receptor signaling: implications for the treatment of cancer. Oncogene (2008) 1.20
Central role of liver in anticancer and radioprotective activities of Toll-like receptor 5 agonist. Proc Natl Acad Sci U S A (2013) 1.16
IL-13R(alpha)2, a decoy receptor for IL-13 acts as an inhibitor of IL-4-dependent signal transduction in glioblastoma cells. Cancer Res (2002) 1.15
TLR9 signaling in the tumor microenvironment initiates cancer recurrence after radiotherapy. Cancer Res (2013) 1.14
Cytokine-induced apoptosis in epithelial HT-29 cells is independent of nitric oxide formation. Evidence for an interleukin-13-driven phosphatidylinositol 3-kinase-dependent survival mechanism. J Biol Chem (1999) 1.11
CpG oligodeoxynucleotides as TLR9 agonists: therapeutic applications in cancer. BioDrugs (2009) 1.06
TLR2 and TLR4 stimulation differentially induce cytokine secretion in human neonatal, adult, and murine mononuclear cells. J Interferon Cytokine Res (2004) 1.04
IL-13 receptor alpha 2: a regulator of IL-13 and IL-4 signal transduction in primary human fibroblasts. J Allergy Clin Immunol (2006) 1.01
TLR9 agonist protects mice from radiation-induced gastrointestinal syndrome. PLoS One (2012) 1.00
Akt-2 binds to Glut4-containing vesicles and phosphorylates their component proteins in response to insulin. J Biol Chem (1999) 0.99
Advances in radiotherapy and targeted therapies for rectal cancer. World J Gastroenterol (2014) 0.98
Flagellin promotes the proliferation of gastric cancer cells via the Toll-like receptor 5. Int J Mol Med (2011) 0.97
TLR2-dependent induction of IL-10 and Foxp3+ CD25+ CD4+ regulatory T cells prevents effective anti-tumor immunity induced by Pam2 lipopeptides in vivo. PLoS One (2011) 0.96
Toll-like receptors: cost or benefit for cancer? Curr Pharm Des (2010) 0.96
A novel systemically administered Toll-like receptor 7 agonist potentiates the effect of ionizing radiation in murine solid tumor models. Int J Cancer (2014) 0.95
Interleukin-13 (IL-13)/IL-13 receptor alpha1 (IL-13Ralpha1) signaling regulates intestinal epithelial cystic fibrosis transmembrane conductance regulator channel-dependent Cl- secretion. J Biol Chem (2011) 0.94
Blockade of TLR3 protects mice from lethal radiation-induced gastrointestinal syndrome. Nat Commun (2014) 0.91
TLR2 limits development of hepatocellular carcinoma by reducing IL18-mediated immunosuppression. Cancer Res (2015) 0.90
Non-immunologically-mediated cytotoxicity of Lactobacillus casei and its derivative peptidoglycan against tumor cell lines. Cancer Lett (1994) 0.86
Immune-mediated signaling in intestinal goblet cells via PI3-kinase- and AKT-dependent pathways. Am J Physiol Gastrointest Liver Physiol (2008) 0.84
TLR9 is critical for glioma stem cell maintenance and targeting. Cancer Res (2014) 0.83
The TLR7 agonist imiquimod as an adjuvant for radiotherapy-elicited in situ vaccination against breast cancer. Oncoimmunology (2013) 0.83
The TLR7 agonist induces tumor regression both by promoting CD4⁺T cells proliferation and by reversing T regulatory cell-mediated suppression via dendritic cells. Oncotarget (2015) 0.82
Interleukin-13 and its receptors in colorectal cancer (Review). Biomed Rep (2013) 0.80
The dark side of Toll-like receptor signaling: TLR9 activation limits the efficacy cancer radiotherapy. Oncoimmunology (2014) 0.80
Interleukin-13 protects mouse intestine from ischemia and reperfusion injury through regulation of innate and adaptive immunity. Transplantation (2011) 0.79
Flagellin and LPS each restores rat lymphocyte populations after colorectal irradiation. J Leukoc Biol (2014) 0.79
Lentiviral-mediated interleukin-4 and interleukin-13 RNA interference decrease airway inflammation and hyperresponsiveness. Hum Gene Ther (2011) 0.79
Keratinocytes treated with peptidoglycan from Staphylococcus aureus produce vascular endothelial growth factor, and its expression is amplified by the subsequent production of interleukin-13. Int J Dermatol (2009) 0.78
Radioprotector WR-2721 and mitigating peptidoglycan synergistically promote mouse survival through the amelioration of intestinal and bone marrow damage. J Radiat Res (2015) 0.76